A new paradigm for improving oral absorption of drugs in discovery: Role of physicochemical properties, different excipients and the pharmaceutical scientist

Future Medicinal Chemistry

Volumn 2, Issue 1, 2010, Pages 1-5

  Wilson, Alan G E ^a   Nouraldeen, Amr ^a   Gopinathan, Suma ^a  

^a LEXICON PHARMACEUTICALS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EXCIPIENT;

DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG DISPOSITION; DRUG FORMULATION; DRUG SCREENING; DRUG SOLUBILITY; EDITORIAL; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; SCIENTIST;

ADMINISTRATION, ORAL; CHEMISTRY, PHARMACEUTICAL; DRUG DISCOVERY; EXCIPIENTS; HUMANS; MODELS, BIOLOGICAL; PHARMACEUTICAL PREPARATIONS; SKIN ABSORPTION;

EID: 77953423449     PISSN: 17568919     EISSN: None     Source Type: Journal    
DOI: 10.4155/fmc.09.146     Document Type: Editorial

References (18)

1. Cuatrecasas P. Interview with Pedro Cuatrecasas. Nat. Rev. Drug Discov. 8, 446 (2009).
2. Gopinathan S, Nouraldeen A, Wilson AGE. Development and application of a high throughput formulation screening strategy in drug discovery. Curr. Drug Discovery Tech. (2009) (In Press).
3. Sastry SV, Nyshadham JR, Fix JA. Recent technological advances in oral drug delivery - a review. Pharmaceut. Sci. Tech. Today 3, 138-145 (2000).
4. Gupta H, Bhandari D, Sharma A. Recent trends in oral drug delivery: a review. Recent Pat. Drug Deliv. Formulation 3, 162-173 (2009).
5. Singh BN, Kim KH. Drug delivery: oral route. In: Encyclopedia of Pharmaceutical Technology (3rd Edition). Informa Healthcare, London, UK 1242-1265 (2006).
6. Maas J, Kamm W, Hauck G. An integrated early formulation strategy - from hit evaluation to preclinical candidate profiling. Eur. J. Pharm. Biopharm. 66, 1-10 (2007).
7. Neervannan N. Preclinical formulations for discovery and toxicology: physicochemical challenges. Expert Opin. Drug Metabol. Toxicol. 2, 715-731 (2006).
8. Li P, Zhao L. Developing early formulations: practice and perspective. Int. J. Pharm. 341, 1-19 (2007).
9. Venkatesh S, Lipper RA. Role of the development scientist in compound lead selection and optimization. J. Pharm. Sci. 89, 145-154 (2000).
10. Lee YC, Zocharski PD, Samas B. An intravenous formulation decision tree for discovery compound formulation development. Int. J. Pharm. 253, 111-119 (2003).
11. Gonzalez RCB, Huwyler J, Walter I, Mountfield R, Bittner B. Improved oral bioavailability of cyclosporin A in male Wistar rats: comparison of a Solutol HS 15 containing self-dispersing formulation and a microsuspension. Int. J. Pharm. 245, 143-151 (2002).
12. Klein S, Wempe MF, Zoeller T et al. Improving glyburide solubility and dissolution by complexation with hydroxybutenyl-b-cyclodextrin. J. Pharm. Pharmacol. 61, 23-30 (2009).
13. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Delivery Rev. 46, 3-26 (2001).
14. Gould S, Scott RC. 2-hydroxypropyl-b-cyclodextrin (HP-b-CD): a toxicology review. Food Chem. Toxicol. 43, 1451-1459 (2005).
15. Gad SC, Cassidy CD, Aubert N, Spainhour B, Robbe H. Nonclinical vehicle use in studies by multiple routes in multiple species. Int. J. Toxicol. 25, 499-521 (2006).
16. Pestel S, Martin H-J, Maier G-M, Guth B. Effect of commonly used vehicles on gastrointestinal, renal, and liver function in rats. J. Pharmacol. Toxicol. Methods 54, 200-214 (2006).
17. Strickley G. Solubilizing excipients in oral and injectable formulations. Pharm. Res. 21, 201-230 (2004).
18. Kola I, Landis J. Can the pharmaceutical industry reduce attrition rates? Nat. Rev. Drug Discov. 3(8), 711-715 (2004).